^
    2d
    A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy (clinicaltrials.gov)
    P1, N=36, Recruiting, Children's Oncology Group | Trial completion date: Jun 2026 --> Mar 2028 | Trial primary completion date: Jun 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    NF1 (Neurofibromin 1) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11)
    |
    RAS mutation • CBL mutation
    |
    cytarabine • methotrexate • leucovorin calcium • fludarabine IV • Rytelo (imetelstat) • Starasid (cytarabine ocfosfate)
    3d
    D7770C00001: A study of AZD2962, an IRAK4 inhibitor, in Participants with Haematologic Neoplasms (2025-520786-44-00)
    P1/2, N=7, Suspended, AstraZeneca AB | Recruiting --> Suspended
    Trial suspension
    5d
    TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT (clinicaltrials.gov)
    P1, N=50, Not yet recruiting, Stanford University | Initiation date: Feb 2026 --> Jun 2026
    Trial initiation date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    6d
    Clinical and Genetic Characterization of Noonan Syndrome in a Colombian Pediatric Cohort. (PubMed, J Clin Res Pediatr Endocrinol)
    These findings underscore the genetic heterogeneity of NS and emphasize the importance of early molecular diagnosis to guide clinical management. Multidisciplinary follow-up is essential due to the risks of growth failure, cardiac anomalies, and malignancies.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • NF1 (Neurofibromin 1) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase) • LZTR1 (Leucine Zipper Like Transcription Regulator 1)
    7d
    Abnormal Eosinophils With Large, Distinctly Basophilic Granules (Harlequin Cells) on Peripheral Blood Smear: A Clue for Diagnosing Chronic Myeloid Leukemia. (PubMed, J Hematol)
    In the appropriate clinical context, strictly defined Harlequin cells on routine peripheral blood smears may serve as a sensitive and highly specific morphologic clue for CML. Recognition of this readily accessible feature may facilitate prompt BCR::ABL1 confirmatory testing, reduce diagnostic ambiguity, and help avoid unnecessary ancillary studies.
    Journal
    |
    ABL1 (ABL proto-oncogene 1)
    |
    CBFB-MYH11 fusion
    8d
    Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX) (clinicaltrials.gov)
    P2, N=75, Not yet recruiting, University of Manitoba
    New P2 trial
    9d
    A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) (clinicaltrials.gov)
    P2, N=52, Not yet recruiting, BioLite, Inc. | Trial completion date: Jun 2028 --> Dec 2028 | Trial primary completion date: Dec 2027 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    azacitidine
    11d
    CMML2AML: machine-learning discovery of co-mutations and specific single mutations predictive of blast transformation in chronic myelomonocytic leukemia. (PubMed, Blood Cancer J)
    The prognostic relevance of "NRAS + SETBP1", "ASXL1 + RUNX1", NPM1 and BCOR was validated in an external cohort from Italy (N = 501). Taken together, these observations highlight i) the possibility of prognostic interaction of mutations in CMML that should be considered in the development of future risk models and ii) the distinct genotypic and prognostic characteristics of NPM1-mutated CMML.
    Journal
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • JAK2 (Janus kinase 2) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • SETBP1 (SET Binding Protein 1) • PHF6 (PHD Finger Protein 6)
    |
    NPM1 mutation • ASXL1 mutation
    14d
    Pathogenic TET2 Variants and Autoinflammatory Manifestations in Myeloid Hematologic Malignancies: Case Report and Literature Review. (PubMed, Eur J Rheumatol)
    Despite initial treatment with corticosteroids and diuretics, her condition worsened, which led to the need to implement treatment with colchicine and anakinra. Eur J Rheumatol. 2026, 13(1), 0119, doi:10.5152/eurjrheum.2026.24119.
    Journal
    |
    TET2 (Tet Methylcytosine Dioxygenase 2)
    |
    Kineret (anakinra)
    16d
    MYELOMONO-3: Cohort of Patients With Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P=N/A, N=5000, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris
    New trial
    20d
    NCI-2020-14163: Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P1/2, N=24, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=44 --> 24
    Enrollment closed • Enrollment change
    |
    TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • SETBP1 (SET Binding Protein 1)
    |
    TP53 mutation • NRAS mutation • ASXL1 mutation
    |
    azacitidine • seclidemstat (SP2577)